Related Experiment Video
Updated: Dec 27, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
Serena Cappuccio1, Maria Grazia Distefano2, Viola Ghizzoni1
1Università Cattolica del Sacro Cuore, Istituto di Clinica Ostetrica e Ginecologica, Roma, Italy.
Abstract:
Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to overcome histology boundaries and to avoid unnecessary toxicity. We describe the case of a patient affected by recurrent high-grade serous ovarian cancer responsive to MEK-inhibitors, who had undergone multiple lines of therapy. To our knowledge, this is the first reported case of recurrent high-grade ovarian cancer showing remarkable clinical, radiologic and biochemical response to trametinib. This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice.
Insights
Recurrent ovarian cancer treatment can be challenging. This case study shows a patient with high-grade serous ovarian cancer responding well to trametinib, a MEK-inhibitor, highlighting potential new treatment avenues.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Recurrent ovarian cancer often presents treatment challenges, necessitating novel therapeutic strategies.
- Tumor genetic testing aids in identifying patient-specific sensitivity profiles for targeted therapies.
- Overcoming histological boundaries and minimizing toxicity are key goals in managing recurrent ovarian cancer.
Observation:
- A patient with recurrent high-grade serous ovarian cancer (HGSC) was treated with multiple prior lines of therapy.
- The patient's tumor exhibited sensitivity to MEK-inhibitors.
- This case represents the first reported instance of HGSC demonstrating significant response to trametinib.
Findings:
- The patient experienced remarkable clinical, radiological, and biochemical response to trametinib (a MEK-inhibitor).
- This response occurred despite prior extensive treatment regimens.
- The findings suggest trametinib's potential efficacy in HGSC, contrasting with existing data primarily on low-grade ovarian cancer.
Implications:
- Molecular profiling is increasingly integral to recurrent ovarian cancer care.
- Trametinib shows promise as a targeted therapy for specific recurrent ovarian cancer subtypes.
- Further randomized clinical trials are essential to validate trametinib's efficacy and establish its role in clinical practice.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...